Epidemiology of myeloproliferative neoplasms in the United States

References

• Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007;110:1092–1097.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Verstovsek S, Cervantes F, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res 2007;31:737–740.
   PubMed Web of Science ®Google Scholar
• Vener C, Fracchiolla NS, Gianelli U, et al. Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis. Blood 2008;111:1862–1865.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Li CY, Ketterling RP et al. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 2005;105:973–977.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Schwager S, Radia D, et al. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res 2009;33:1199–1203.
   PubMed Web of Science ®Google Scholar
• Scherber R, Dueck AC, Johansson P et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood 2011;118:401–408.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004;117:755–761.
   PubMed Web of Science ®Google Scholar
• Breslow NE, Day NE. Indirect standardization and multiplicative models for rates, with reference to the age adjustment of cancer incidence and relative frequency data. J Chron Dis 1975;28: 289–303.
   PubMedGoogle Scholar
• Johansson P, Kutti J, Andreasson B, et al. Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Göteborg, Sweden, during 1983-99. J Intern Med 2004;256:161–165.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Silverstein MN, Jacobsen SJ, et al. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted county study, 1976–1995. Am J Hematol 1999;61:10–15.
   PubMed Web of Science ®Google Scholar
• Girodon F, Bonicelli G, Schaeffer C, et al. Significant increase in the apparent incidence of essential thrombocythemia related to new WHO diagnostic criteria: a population-based study. Haematologica 2009;94:865–869.
   PubMed Web of Science ®Google Scholar
• Phekoo KJ, Richards MA, Moller H, et al. The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England. Haematologica 2006;91:1400–1404.
   PubMed Web of Science ®Google Scholar
• Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood 2008;112:45–52.
   PubMed Web of Science ®Google Scholar
• Policitemia GIS. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med 1995;123:656–664.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Rumi E, Arcaini L, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica 2008;93:1645–1651.
   PubMed Web of Science ®Google Scholar
• Cervantes F, Passamonti F, Barosi G. Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia 2008;22:905–914.
   PubMed Web of Science ®Google Scholar
• Berglund S, Zettervall O. Incidence of polycythemia vera in a defined population. Eur J Haematol 1992;48:20–26.
   PubMed Web of Science ®Google Scholar
• Bender GP, Young D, Balcerzak SP. Polycythemia vera in a small Ohio town. Ohio State Med J 1986;82:631, 633, 635.
   PubMedGoogle Scholar
• Ma X, Vanasse G, Cartmel B, et al. Prevalence of polycythemia vera and essential thrombocythemia. Am J Hematol 2008;83:359–362.
   PubMed Web of Science ®Google Scholar
• Jensen MK, de Nully Brown P, Nielsen OJ, et al. Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area. Eur J Haematol 2002;65:132–139.
   Web of Science ®Google Scholar
• Abdel-Wahab OI, Levine RL. Primary myelofibrosis: update on definition, pathogenesis, and treatment. Annu Rev Med 2009;60: 233–245.
   PubMed Web of Science ®Google Scholar